Use of Liquid Chromatography-Tandem Mass Spectrometry for Clinical Testing in Korean Laboratories: a Questionnaire Survey

Hyojin Chae, M.D., Sung-Eun Cho, M.D., Hyung-Doo Park, M.D., Sail Chun, M.D., Yong-Wha Lee, M.D., Yeo-Min Yun, M.D., Sang-Hoon Song, M.D., Sang-Guk Lee, M.D., Kyunghoon Lee, M.D., Junghan Song, M.D., and Soo-Youn Lee, M.D.; On behalf of the Clinical Mass Spectrometry Research Committee of Korean Society of Clinical Chemistry

1Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea; 2LabGenomics Clinical Laboratories, Seongnam, Korea; 3Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 4Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea; 5Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea; 6Department of Laboratory Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; 7Department of Laboratory Medicine, Seoul National University Hospital and College of Medicine, Seoul, Korea; 8Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; 9Department of Laboratory Medicine, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Korea

Background: The use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) has substantially increased in clinical laboratories worldwide. To assess the status of clinical LC-MS/MS testing in Korean laboratories, a questionnaire survey was performed by the Clinical Mass Spectrometry Research Committee of the Korean Society of Clinical Chemistry.

Methods: The questionnaire was distributed to 19 clinical laboratories performing clinical LC-MS/MS from April to May 2018. It asked about general characteristics of the laboratory and commonly utilized clinical LC-MS/MS tests: newborn screening, tacrolimus test, vitamin D test, and plasma metanephrine test. Frequency analysis and other statistical analyses were performed.

Results: A total of 17 laboratories responded. The median number of LC-MS/MS instruments, laboratory medicine physicians, and technicians in each laboratory was three, one, and two, respectively. Nine laboratory directors had >10 years of experience with clinical LC-MS/MS. For each LC-MS/MS test, at least two concentrations of QC materials were measured every 24 hours during clinical testing, and all laboratories used QC acceptability criteria based on their established QC means and SDs. All laboratories participated in an external quality assessment program. However, there was inter-laboratory variability in sample preparation methods, instruments, reagents, internal standards, and calibrators.

Conclusions: LC-MS/MS has been successfully introduced in Korean clinical laboratories and is used within a quality framework. Further efforts for harmonization on a nationwide basis could facilitate the widespread use of LC-MS/MS.

Key Words: Liquid chromatography-tandem mass spectrometry, Korea, Survey, Harmonization
INTRODUCTION

Mass spectrometry (MS) represents a key technology in biomedical research areas, such as proteomics, pharmacology, and metabolomics [1]. With the advent of soft ionization techniques, such as electrospray ionization (ESI) and matrix-assisted laser desorption ionization (MALDI), the use of liquid chromatography-tandem MS (LC-MS/MS) has substantially increased in clinical laboratories [2, 3]. Current clinical applications of LC-MS/MS include screening for inherited metabolic disorders, measurement of numerous small-molecule biomarkers, and quantification of drugs and their metabolites [1]. The strengths of LC-MS/MS are its high selectivity and sensitivity, capability for multi-analyte analyses, and high throughput.

As an effort to popularize and improve the use of LC-MS/MS in clinical laboratories across Korea, a questionnaire survey was conducted by the Clinical Mass Spectrometry Research Committee (CMSRC) of the Korean Society of Clinical Chemistry (KSCC). It aimed to provide an accurate and updated overview of clinical LC-MS/MS testing in Korean clinical laboratories and shed light on the challenges of using LC-MS/MS in this setting.

METHODS

Survey population
The survey population consisted of all 19 clinical laboratories performing clinical LC-MS/MS tests in medical institutions (hospitals and medical centers) and referral medical laboratories accredited by the Korean Laboratory Accreditation Program (KO-LAS) [4]. The survey was performed from April to May 2018. The questionnaire was e-mailed to the directors and laboratory physicians in charge of these 19 laboratories. This study was approved by the Institutional Review Board (IRB)/Ethics Committee of Seoul St. Mary’s Hospital, Korea (IRB No. KC18QCDI0566).

Questionnaire
The questionnaire was in Korean, with multiple-choice questions, and consisted of two sections. The first comprised questions on the general characteristics of the LC-MS/MS laboratory: type of medical institution; number of LC-MS/MS instruments; number of LC-MS/MS laboratory physicians, technicians, and researchers; years of experience with clinical LC-MS/MS tests; clinical LC-MS/MS tests performed; laboratory area; and instrument management (nitrogen gas supply and preventive maintenance plans).

The second section comprised questions on four commonly utilized clinical diagnostic tests: newborn screening test (NST), tacrolimus test, vitamin D test, and plasma metanephrine test. The questionnaire asked about sample pretreatment and sample volume, test volume, turnaround time (TAT), testing frequency, calibrators, internal standards, reagents, internal quality control, test reporting, proficiency testing, and components of method validation.

Data analysis
An Excel spreadsheet was used to summarize the data. Categorical data were summarized as frequency and percentage.

Table 1. Clinical LC-MS/MS tests performed in 17 clinical laboratories in Korea

| Test Type                      | Laboratories, N (%) |
|--------------------------------|---------------------|
| Newborn screening              |                     |
| Amino acid/organic acid/fatty acid disorders | 11 (65)          |
| Galactosemia                   | 2 (12)              |
| Krabbe disease                 | 1 (6)               |
| Lysosomal storage disorders    | 3 (18)              |
| Therapeutic drug monitoring    |                     |
| Immunosuppressants             | 9 (53)              |
| Anti-infective agents          | 6 (35)              |
| Anticonvulsants                | 6 (35)              |
| Antidepressants/antipsychotics | 2 (12)              |
| Anticancer agents              | 2 (12)              |
| Amiodarone                     | 1 (6)               |
| Drugs of abuse                 | 3 (18)              |
| Metabolite/hormones            |                     |
| 5-HIAA                         | 1 (6)               |
| Metanephrines                  | 7 (41)              |
| Amino acids                    | 3 (18)              |
| Acylcarnitines                 | 2 (12)              |
| Carnitine                      | 3 (18)              |
| Homocysteine                   | 4 (24)              |
| Methylmalonic acid             | 1 (6)               |
| Citrate                        | 1 (6)               |
| Oxalate                        | 1 (6)               |
| Steroid profile                | 1 (6)               |
| Cortisol                       | 1 (6)               |
| Catecholamines                 | 2 (12)              |
| Aldosterone                    | 2 (12)              |
| Vitamin D                      | 9 (53)              |

Abbreviations: LC-MS/MS, liquid chromatography-tandem mass spectrometry; HIAA, hydroxyindoleacetic acid.
and continuous data were summarized as median and range. Normality was assessed using the D’Agostino and Pearson normality test. The association between the types of the clinical laboratory and TAT or test volume was evaluated using Fisher’s exact tests. The correlation between the number of LC-MS/MS instruments and the number of laboratory medicine physicians, the number of laboratory technicians, and the number of clinical LC-MS/MS tests was assessed using Pearson’s correlation coefficient. GraphPad Prism 7.05 (GraphPad Software, San Diego, CA, USA) was used for statistical analyses. P < 0.05 was considered statistically significant.

RESULTS

Laboratory characteristics
Seventeen laboratories (11 university hospitals and six referral medical laboratories) responded. The median number of LC-MS/MS instruments was three (range, 1–10). The median number of laboratory medicine physicians was one (range, 1–3), and the median number of laboratory technicians was two (range, 1–5). Nine laboratory directors had > 10 years and 35% had 5–10 years of experience with clinical LC-MS/MS tests (for a list of tests, see Table 1).

When the general characteristics of LC-MS/MS clinical laboratories were compared according to the type of institution, the median number of LC-MS/MS instruments was higher in referral medical laboratories than university hospitals (P = 0.0300). Referral medical laboratories performed more NSTs (P = 0.0022) and tended to perform more tacrolimus tests (P = 0.0833) than university hospitals. Referral medical laboratories tended to have a faster TAT for NST than university hospitals (P = 0.0606). The number of LC-MS/MS instruments moderately correlated with the number of laboratory medicine physicians (r = 0.5482, P = 0.0227), strongly correlated with the number of laboratory technicians (r = 0.6853, P = 0.0016), and weakly correlated with the number of clinical LC-MS/MS tests (r = 0.3808, P = 0.0876).

Table 2. Laboratory operation/management issues

| Laboratories, N (%) | NST (N = 11) | Tacrolimus (N = 9) | Vitamin D (N = 9) | Plasma metanephrines (N = 6) |
|---------------------|--------------|-------------------|------------------|-----------------------------|
| Test volume (per month) |              |                   |                  |                             |
| <50                 | 5 (45)       | 2 (22)            | 2 (22)           | 1 (17)                      |
| 50–100              | 1 (11)       | 0                 | 1 (17)           |                             |
| 100–200             | 3 (33)       | 3 (33)            | 1 (17)           |                             |
| 200–500             | 1 (11)       | 2 (22)            | 2 (33)           |                             |
| 500–2,500           | 2 (22)       | 2 (22)            | 1 (17)           |                             |
| 2,500–5,000         | 3 (27)       | 0                 | 0                |                             |
| 5,000 ≤             | 3 (27)       | 0                 | 0                |                             |
| Batch size |              |                   |                  |                             |
| <10                 | NA           | 2 (22)            | 2 (22)           | 0                           |
| 10–20               | 3 (33)       | 1 (11)            | 2 (33)           |                             |
| 20–50               | 3 (33)       | 3 (33)            | 1 (17)           |                             |
| 50 ≤                | 1 (11)       | 3 (33)            | 3 (50)           |                             |
| TAT |              |                   |                  |                             |
| 1 day               | 0            | 4 (44)            | 0                | 0                           |
| <3 days             | 8 (72)       | 5 (55)            | 8 (88)           | 5 (83)                      |
| <7 days             | 3 (27)       | 0                 | 0                | 1 (17)                      |
| Testing frequency   |              |                   |                  |                             |
| Daily               | 6 (55)       | 6 (66)            | 3 (33)           | 0                           |
| 2–4/week            | 4 (36)       | 3 (33)            | 4 (44)           | 6 (100)                     |
| Once/week           | 1 (9)        | 0                 | 2 (22)           | 0                           |
| Other               | 0            |                  |                  |                             |
| Weekend             | 5 (55)       |                   |                  |                             |
| Test order and reporting |          |                   |                  |                             |
| Manual              | 3 (27)       | 6 (67)            | 6 (67)           | 5 (83)                      |
| Unidirectional interface | 8 (73)     | 3 (33)            | 3 (33)           | 1 (17)                      |
| Type of reporting   |              |                   |                  |                             |
| Numerical report    | 0            | 9 (100)           | 8 (88)           | 6 (100)                     |
| Text report         | 11 (100)     | 3 (33)            | 2 (22)           | 1 (17)                      |

Abbreviations: NST, newborn screening test; TAT, turnaround time; NA, not available.
nicians \( r=0.6793, P=0.0027 \), and strongly correlated with the number of clinical MS tests \( r=0.7146, P=0.0013 \).

**LC-MS/MS tests**

Tables 2 and 3 summarize responses on test-specific laboratory operational/management issues and methodological issues, respectively.

NSTs represented the highest volume of LC-MS/MS tests, with over half of the laboratories performing >2,500 tests per month. For tacrolimus, vitamin D, and plasma metanephrine tests, over half of the laboratories performed <200 tests per month. Over half reported a target TAT of <72 hours for all four tests (Table 2).

All laboratories used a stable isotope-labeled internal standard for the vitamin D and plasma metanephrine tests. However, for tacrolimus testing, 78% of the laboratories used a non-isotopic internal standard, ascomycin. The majority of laboratories used

**Table 3. Test-specific methodological issues**

|                     | NST (N=11) | Tacrolimus (N=9) | Vitamin D (N=9) | Plasma metanephrines (N=6) |
|---------------------|------------|------------------|-----------------|---------------------------|
| Sample pretreatment | Derivatization | Protein precipitation with acetonitrile | 8 (89) | Solid phase extraction | 1 (11) | Solid phase extraction | 5 (83) |
|                     | Non-derivatized | Protein precipitation with methanol | 1 (11) | Liquid-liquid extraction | 6 (67) | Protein precipitation | 1 (17) |
|                     | Protein precipitation | 3 (33) |                |                           |        |                     |
| Type of reagent     | Prepared in-house | 7 (64) | 0 | 3 (33) | 5 (83) |
|                     | Commercially purchased | 5 (45) | 9 (100) | 3 (33) | 1 (17) |
|                     | Both | 3 (33) |                |                           |        |                     |
| Type of internal standard | Isotope-labeled | NA | 2 (22) | 9 (100) | 6 (100) |
|                     | Non-isotope-labeled | NA | 7 (78) | 0 | 0 |
| Type of calibration material | Commercially purchased | NA | 9 (100) | 8 (89) | 0 |
|                     | Prepared in-house | NA | 0 | 1 (11) | 6 (100) |
|                     | 3 (33) |                |                           |
| Type of matrix      | Matrix-matched | NA | 9 (100) | 9 (100) | 4 (66) |
|                     | Matrix-unmatched | NA | 0 | 0 | 2 (33) |
| Calibrators, N      | NA | 0 | 2 (22) | 2 (33) |
|                     | 3,4 | 0 | 2 (22) | 2 (33) |
|                     | 5,6 | 7 (78) | 2 (22) | 2 (33) |
|                     | >6 | NA | 5 (56) | 2 (33) |
| Type of QC material | Commercially purchased | 6 (55) | 9 (100) | 9 (100) | 4 (66) |
|                     | Prepared in-house | 1 (9) | 0 | 0 | 2 (33) |
|                     | Others | CDC 7 (64) |                |                           |
| Concentrations of QC material [median (range)] | AA 2 (2–4) | 3 (3–4) | 2 (2–3) | 2 (2–3) |
| QC frequency per plate | 55 (6) | 1 (11) | 2 (22) | 1 (17) |
|                   | per run | 0 | 2 (22) | 3 (33) | 1 (17) |
|                   | daily | 5 (45) | 6 (67) | 4 (45) | 4 (66) |
| Participating EQA programs | KEQAS | 11 (100) | 9 (100) | 5 (63) | 6 (100) |
|                     | CDC | 11 (100) | NA | 1 (13) | NA |
|                     | CAP | 0 | 5 (56) | 8 (100) | 1 (17) |
|                     | Others | PPFK 10 (92) | DEQAS 2 (25) | RCPA 2 (33) | VitDQAP 1 (13) |

Abbreviations: NST, newborn screening test; NA, not available; CDC, Centers for Disease Control and Prevention; AA, amino acids; AC, acylcarnitines; KEQAS, Korean Association of External Quality Assessment Service; PPFK, Planned Population Federation of Korea; CAP, College of American Pathologists; DEQAS, Vitamin D External Quality Assessment Scheme; VitDQAP, Vitamin D Metabolites Quality Assurance Program; RCPA, The Royal College of Pathologists of Australasia; EQA, external quality assessment.
DISCUSSION

This survey summarizes the current practices and characteristics of clinical LC-MS/MS laboratories in Korea. It shows that LC-MS/MS has been successfully introduced in many clinical laboratories, with major applications in newborn screening, therapeutic drug monitoring, endocrinology, and nutritional assessment. The expansion and integration of LC-MS/MS into clinical laboratories are reflected in its proportion in EQA programs and in the fact that 7% and 2% of all participating laboratories in the 2018 KEQAS EQA scheme use LC-MS/MS for tacrolimus and vitamin D testing, respectively.

However, the number of clinical LC-MS/MS laboratories in Korea (19) is still small, only 6% of the total number of clinical laboratories accredited by the KOLAS (305). Further, clinical LC-MS/MS laboratories are limited to university hospitals (65%) and large referral medical laboratories (35%). The proportion of LC-MS/MS in Korean EQA programs is lower than that in global EQA programs (17% and 10% of all participating laboratories for tacrolimus and vitamin D tests, respectively) [5]. Therefore, considering the global growth of clinical LC-MS/MS tests, there is still room for further expansion of LC-MS/MS in Korea.

The original sample preparation methods for the LC-MS/MS NST used butyl esterification (derivatization). However, with the improved sensitivity of MS instruments, it is possible to detect amino acids and acylcarnitines as their native free acids (non-derivatized). We found that the proportion of derivatization and non-derivatized sample preparation methods used was similar, in accordance with recent CDC NST QC data summaries [6]. Protein precipitation is the most commonly used method for extracting immunosuppressants because it is simple, cheap, and less time-consuming [7]. For the vitamin D tests, 67% and 33% of all laboratories used liquid-liquid extraction and protein precipitation methods, respectively, similar to the proportions reported in the vitamin D EQA Scheme (DEQAS) data [8]. To analyze plasma metanephrines, solid phase extraction has been the sample preparation method of choice [9]. In the present survey, all but one laboratory used solid phase extraction for sample preparation.

The addition of an internal standard to samples before analysis represents the single most valuable method enhancement that MS can offer [10]. All responding laboratories used methods that included the use of an internal standard. The majority of laboratories used a stable isotope-labeled form of the measured analyte. However, for tacrolimus, a non-isotopic internal standard, ascomycin, was used by the majority of laboratories.

Table 4. Components of method validation

| Laboratories, N (%) | NST (N = 9) | Tacrolimus (N = 8) | Vitamin D (N = 9) | Plasma metanephrines (N = 6) |
|-------------------|-------------|--------------------|------------------|-----------------------------|
| Accuracy          | 6 (67)      | 7 (88)             | 9 (100)          | 6 (100)                     |
| Precision         | 9 (100)     | 8 (100)            | 9 (100)          | 6 (100)                     |
| Linearity         | 5 (56)      | 8 (100)            | 9 (100)          | 6 (100)                     |
| Comparison        | 6 (67)      | 8 (100)            | 9 (100)          | 4 (67)                      |
| Carry-over        | 6 (67)      | 7 (88)             | 9 (100)          | 6 (100)                     |
| Recovery          | 4 (44)      | 7 (88)             | 8 (89)           | 6 (100)                     |
| Limit of detection| 3 (33)      | 3 (38)             | 4 (44)           | 3 (50)                      |
| Limit of quantification| 2 (22)   | 8 (100)            | 8 (89)           | 6 (100)                     |
| Ion suppression and matrix effect | 2 (22) | 7 (88) | 6 (67) | 5 (83) |
| Batch size        | 1 (11)      | 1 (13)             | 1 (11)           | 1 (17)                      |
| SST               | 0           | 1 (13)             | 2 (22)           | 1 (17)                      |
| Interferences     | 0           | 3 (38)             | 3 (33)           | 2 (33)                      |
| Stability         | 0           | 6 (75)             | 2 (22)           | 3 (50)                      |

Abbreviations: SST, system suitability test; NST, newborn screening test.
Although a recent study did not observe any differences between the use of ascomycin and an isotope-labeled internal standard, tacrolimus-\textsubscript{13}C\textsubscript{2}D\textsubscript{2} [11], other studies reported better results using tacrolimus-\textsubscript{13}C\textsubscript{2}D\textsubscript{2} than ascomycin [12]. With the recent availability of commercial isotope-labeled internal standards for immunosuppressants (e.g., Chromsystems, Munich, Germany, or Recipe, Munich, Germany), the use of isotope-labeled internal standards in immunosuppressant LC-MS/MS tests is likely to increase in the near future.

Regarding quality assurance and QC for LC-MS/MS, the CLSI document C62-A suggests that a minimum of two concentrations of QC materials should be measured at least every 24 hours during patient testing [10]. We found that at least two concentrations of QC materials were measured for each LC-MS/MS test, and all laboratories were using QC acceptability criteria based on their own established QC means and SDs derived from repetitive analysis of control materials. All laboratories reported participation in one or more EQA programs. As EQA is one of the most preferred methods for assessing test accuracy, these laboratories reported using LC-MS/MS within a quality framework that addresses both internal and external quality assurance.

One of the potential obstacles preventing the adoption of LC-MS/MS in routine clinical laboratories is the seemingly overwhelming method validation requirements required to meet the guidelines for clinical applications. Although there are multiple guidelines for the validation of bioanalytical methods [13-15], including the CLSI C62-A [10], regulatory requirements differ somewhat across countries and laboratory accreditation agencies. In this regard, the development of regional/national guidelines for LC-MS/MS validation for clinical laboratories that address regional regulations could facilitate the use of LC-MS/MS in medium-sized community hospitals and regional clinical laboratories in Korea.

This study has some limitations. Because this survey was an initiative of the CMSRC of the KSCC, it focused primarily on LC-MS/MS testing in clinical chemistry applications. Thus, other areas of clinical MS, such as gas chromatography-MS, inductively coupled plasma MS, and matrix-assisted laser desorption ionization time-of-flight MS (MALDI-TOF MS), in clinical microbiology were not assessed. Another limitation was the fact that the number of responding laboratories was relatively low, making it difficult to draw definitive conclusions.

However, this survey is the first to describe various aspects of LC-MS/MS in clinical laboratories in Korea. Furthermore, it is important to understand the current status of clinical LC-MS/MS laboratory practices to form a basis upon which future harmonization and advancements can be made. Further studies attempting to harmonize and enhance the analytical robustness of LC-MS methods on a nationwide basis will be necessary.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**Acknowledgements**

This study was supported by the Clinical Mass Spectrometry Research Committee of the Korean Society of Clinical Chemistry.

**ORCID**

Hyojin Chae https://orcid.org/0000-0001-5870-1887

Sung-Eun Cho https://orcid.org/0000-0001-8082-3100

Hyung-Doo Park https://orcid.org/0000-0003-1798-773X

Sail Chun https://orcid.org/0000-0002-5792-973X

Yong-Wha Lee https://orcid.org/0000-0002-4459-6286

Yeo-Min Yun https://orcid.org/0000-0002-5485-8331

Sang-Hoon Song https://orcid.org/0000-0002-5084-1137

Sang-Guk Lee https://orcid.org/0000-0003-3862-3660

Kyunghoon Lee https://orcid.org/0000-0002-3154-0347

Junghan Song https://orcid.org/0000-0003-0576-9938

Soo-Youn Lee https://orcid.org/0000-0001-7595-4042

**REFERENCES**

1. Taylor PJ. High-performance liquid chromatography-mass spectrometry in the clinical laboratory. Ther Drug Monit 2005;27:689-93.

2. Dooley KC. Tandem mass spectrometry in the clinical chemistry laboratory. Clin Biochem 2003;36:471-81.

3. Grebe SK and Singh RJ. LC-MS/MS in the clinical laboratory—where to from here? Clin Biochem Rev 2011;32:5-31.

4. Shin BM, Chae SL, Min WK, Lee WG, Lim YA, Lee DH, et al. The implementation and effects of a clinical laboratory accreditation program in Korea from 1999 to 2006. Korean J Lab Med 2009;29:163-70.

5. Greaves RF. Recent advances in the clinical application of mass spectrometry. EJIFCC 2016;27:264-71.

6. CDC. Newborn Screening Quality Assurance Program 2018 Quality Control Report. https://www.cdc.gov/labstandards/pdf/nsqap/nsqap_2018_qcset1_report.pdf (Issued June 8, 2018).

7. Al-Jenoobi FI, Alam MA, Al-Mohizea AM. Quantification of immunosuppressant’s in blood using LC-MS/MS. Austrin Chromatogr 2016:3;1039.

8. Couchman L, Benton CM, Moniz CF. Variability in the analysis of 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry.
the devil is in the detail. Clin Chim Acta 2012;413:1239-43.
9. Marney LC, Laha TJ, Baird GS, Rainey PM, Hoofnagle AN. Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1729-32.
10. CLSI. Liquid chromatography-mass spectrometry methods; approved guideline. CLSI C62-A. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.
11. Valbuena H, Shipkova M, Kliesch SM, Müller S, Wieland E. Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. Clin Chem Lab Med 2016;54:437-46.
12. Buchwald A, Winkler K, Epting T. Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA. BMC Clin Pharmacol 2012;12:2.
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for industry- bioanalytical method validation. https://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf. (Updated on May 2018).
14. European Medicines Agency. Guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. (Updated on July 2011).
15. Scientific Working Group for Forensic Toxicology. Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol 2013;37:452-74.